Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID-tunniste: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Breast cancer remodels lymphatics in sentinel lymph nodes (2025)
- Nature Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Nextpie: a web-based reporting tool and database for reproducible nextflow pipelines (2025)
- Bioinformatics Advances
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer (2023)
- PLoS Computational Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities (2023)
- British Journal of Cancer
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice (2022)
- iScience
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Target-specific compound selectivity for multi-target drug discovery and repurposing (2022)
- Frontiers in Pharmacology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Tumor microenvironment as a metapopulation model: The effects of angiogenesis, emigration and treatment modalities (2022)
- Journal of Theoretical Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia (2021)
- npj Precision Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Crowdsourced mapping of unexplored target space of kinase inhibitors (2021)
- Nature Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Modeling drug combination effects via latent tensor reconstruction (2021)
- Bioinformatics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



